Bristol-Myers Squibb Company stock (US0897961004): Q1 profit beats lift shares on Eliquis and cancer drugs

Bristol-Myers Squibb beat Q1 profit and revenue expectations on strong Eliquis and newer cancer drug sales, sending its stock higher and reinforcing its margin strength heading into 2026.

Bristol-Myers Squibb Company reported first?quarter 2026 results that topped Wall Street expectations, driven by robust sales of the blood thinner Eliquis and newer cancer medicines, which helped offset declines in older products facing generic competition. The company posted adjusted earnings of $1.58 per share on revenue of $11.49 billion, ahead of analyst estimates of about $1.42 per share and $10.9 billion, according to LSEG data cited by the Economic Times and other outlets.Economic Times as of 05/08/2026

Shares of Bristol?Myers Squibb rose about 4% in the wake of the earnings release, reflecting investor relief that the company’s newer growth portfolio is compensating for patent?loss pressures on legacy brands such as Revlimid. The stock traded around the mid?$50s on the NYSE, with a trailing?twelve?month EPS near $3.56 and a trailing net profit margin of about 15%, up from roughly 11.4% a year earlier, according to Simply Wall St and Google Finance data.Simply Wall St as of 05/08/2026Google Finance as of 05/08/2026

As of: 08.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bristol?Myers Squibb Company
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: United States
• Core markets: United States, Europe, Japan and other developed markets
• Key revenue drivers: Oncology, cardiovascular, immunology and cell therapy products
• Home exchange/listing venue: New York Stock Exchange (ticker: BMY)
• Trading currency: US dollar

Bristol?Myers Squibb Company: core business model

Bristol?Myers Squibb is a global biopharmaceutical company focused on discovering, developing and commercializing innovative medicines for serious diseases, particularly in oncology, cardiovascular, immunology and cell therapy. Its business model centers on high?margin branded drugs and therapies that address unmet medical needs, supported by a large?scale commercial infrastructure and long?term partnerships with other major pharmaceutical players.Bristol?Myers Squibb as of 05/08/2026

The company generates most of its revenue from prescription medicines sold in developed markets, with a strong emphasis on specialty care and hospital?based treatments. It relies on patent protection, clinical differentiation and payer negotiations to maintain pricing power, while also investing heavily in research and development to replenish its pipeline as older products face generic or biosimilar competition.Bristol?Myers Squibb as of 05/08/2026

For US investors, Bristol?Myers Squibb offers exposure to a diversified portfolio of branded therapies in high?growth therapeutic areas, including cancer and cardiovascular disease, with a significant portion of sales derived from the US market and a listing on the NYSE that provides liquidity and broad index inclusion.Bristol?Myers Squibb Investor Relations as of 05/08/2026

Main revenue and product drivers for Bristol?Myers Squibb Company

Eliquis, the blood thinner co?marketed with Pfizer, remains one of Bristol?Myers Squibb’s largest revenue drivers, generating $4.14 billion in quarterly sales, up 16% year over year, according to the company’s first?quarter 2026 report. Management highlighted that demand for Eliquis remains strong, with new prescription share exceeding 75%, underscoring its entrenched position in the anticoagulant market.Economic Times as of 05/08/2026

The company’s growth portfolio, which includes newer cancer medicines such as the cell therapy Breyanzi and the heart?failure drug Camzyos, contributed $6.23 billion in sales, up 12% and accounting for more than half of total revenue. This growth helped offset steep declines in older products facing generic competition, including the once?top?selling blood cancer treatment Revlimid, whose sales have been eroding as patents expire.Economic Times as of 05/08/2026

Within oncology, the original formulation of Opdivo generated $2.15 billion in quarterly sales, down 5% and below some analyst estimates, reflecting ongoing competitive pressures and pricing dynamics. Nevertheless, Bristol?Myers Squibb continues to invest in combination regimens and new indications to extend the franchise’s lifecycle and support future revenue streams.Economic Times as of 05/08/2026

Why Bristol?Myers Squibb Company matters for US investors

For US investors, Bristol?Myers Squibb offers a combination of dividend income, exposure to innovative drug development and a diversified portfolio of branded therapies in large, growing markets. The company pays a quarterly dividend of $0.63 per share, implying a dividend yield of about 4.5% at recent price levels, which may appeal to income?oriented equity investors seeking yield in the healthcare sector.Google Finance as of 05/08/2026

US investors also benefit from the company’s strong presence in the domestic healthcare system, where reimbursement and payer dynamics play a key role in shaping drug pricing and volume trends. Bristol?Myers Squibb’s focus on oncology and cardiovascular disease aligns with major chronic?disease trends in the United States, including aging demographics and rising cancer incidence, which underpin long?term demand for its therapies.Bristol?Myers Squibb as of 05/08/2026

At the same time, the stock’s valuation and earnings trajectory are sensitive to regulatory decisions, patent cliffs and competitive launches, meaning US investors must weigh the company’s current margin strength and growth?portfolio momentum against the risk of future revenue erosion from generic and biosimilar competition.Simply Wall St as of 05/08/2026

Conclusion

Bristol?Myers Squibb’s first?quarter 2026 results highlight a company that is successfully navigating patent?loss pressures by leaning on a strong growth portfolio anchored by Eliquis and newer cancer therapies. The beat on both profit and revenue expectations, along with an elevated net profit margin of about 15%, suggests that the company’s cost discipline and product mix are supporting near?term earnings power.Simply Wall St as of 05/08/2026Economic Times as of 05/08/2026

However, investors should remain mindful of the long?term challenge posed by generic and biosimilar competition to legacy brands such as Revlimid and Opdivo, which could weigh on future revenue growth even as newer products ramp up. The stock’s appeal for US investors will depend on how effectively Bristol?Myers Squibb continues to balance margin strength, pipeline innovation and dividend sustainability in a highly regulated and competitive environment.Bristol?Myers Squibb as of 05/08/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.